Spots Global Cancer Trial Database for Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

Official Title: Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastatic Breast or Lung Cancer

Study ID: NCT00059943

Conditions

Breast Cancer

Lung Cancer

Prostate Cancer

Interventions

docetaxel

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well docetaxel works in treating older patients with metastatic breast, lung, or prostate cancer.

Detailed Description: OBJECTIVES: * Determine the pharmacokinetics of docetaxel in older patients with metastatic breast, lung, or prostate cancer. * Determine the response of patients treated with this drug. * Determine the toxicity of this drug in these patients. * Determine the short-term changes in functional status, in terms of activities of daily living, independent activities of daily living, and Karnofsky performance status, in patients treated with this drug. * Correlate the number of comorbid conditions at baseline with declines in functional status in patients treated with this drug. OUTLINE: Patients receive docetaxel IV over 30 minutes once weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.